目的 探討陽離子轉(zhuǎn)運(yùn)蛋白1（SLC22A1）基因在肝細(xì)胞癌中的表達(dá)情況和預(yù)后意義。方法 用The Human Protein Atlas（HAP）數(shù)據(jù)庫分析SLC22A1蛋白在肝細(xì)胞癌中的表達(dá)情況。利用Oncomine和GEPIA數(shù)據(jù)庫分析SLC22A1基因在肝細(xì)胞癌和肝正常組織中的表達(dá)水平。利用GEPIA和Linked Omics數(shù)據(jù)庫分析SLC22A1基因與肝細(xì)胞癌患者臨床相關(guān)性：總生存期（OS）、無瘤生存期（DFS）、病理分期和種族。采用Metascape在線工具對SLC22A1相關(guān)基因進(jìn)行功能和通路富集分析。結(jié)果 LC22A1蛋白和mRNA在肝細(xì)胞癌組織中顯著低于正常組織，且與肝細(xì)胞癌預(yù)后呈正相關(guān)（P<0.001）。肝細(xì)胞癌中SLC22A1基因表達(dá)水平與預(yù)后、病理分期存在顯著差異性（P<0.05），與種族無相關(guān)性。功能富集分析顯示，SLC22A1基因通過影響小分子分解代謝過程、對異源生物刺激的反應(yīng)和有機(jī)酸生物合成過程等發(fā)揮作用。通路富集分析顯示，SLC22A1基因通過作用于過氧化物酶體、脂肪酸降解和精氨酸和脯氨酸代謝等通路起作用。結(jié)論 細(xì)胞癌組織中SLC22A1蛋白和mRNA表達(dá)水平均顯著低于肝正常組織，其表達(dá)情況與肝細(xì)胞癌預(yù)后存在顯著關(guān)聯(lián)，提示SLC22A1可能成為評估肝細(xì)胞癌預(yù)后的指標(biāo)和研發(fā)肝細(xì)胞癌相關(guān)靶向藥物的候選靶點(diǎn)，為肝細(xì)胞癌研究提供新研究思路。

Objective To investigate the expression of cation transporter 1 (SLC22A1) gene and its prognostic significance in hepatocellular carcinoma (HCC). Methods The Human Protein Atlas (HAP) database was used to analyze the expression of SLC22A1 protein in hepatocellular carcinoma. The online tools Oncomine and GEPIA were used to evaluate the expression of SLC22A1 gene in hepatocellular carcinoma. GEPIA and Linked Omics databases were also used to analyze the correlation between COL1A2 and clinical indicators overall survival (OS), tumor-free survival (DFS), pathological stage, and race. Metascape online tools were used to perform functional and pathway enrichment analysis of SLC22A1-related genes. Results SLC22A1 protein and mRNA were highly expressed in normal tissues and was positively correlated with prognosis (P<0.001). The expression levels of SLC22A1 gene in HCC were significantly different from prognosis and pathological stage (P<0.05), and it was not related to race. Functional enrichment analysis showed that the SLC22A1 gene played a role by affecting small molecule catabolic processes, responses to heterologous biological stimuli, and organic acid biosynthesis processes. Pathway enrichment analysis showed that the SLC22A1 gene works through pathways such as peroxisomes, fatty acid degradation, and arginine and proline metabolism. Conclusion SLC22A1 gene and protein is highly expressed in normal tissues, and its expression level is significantly correlated with prognosis, which might be an important therapeutic target and biomarker of HCC.

R979.1